Clinical Report: Evaluating the Effectiveness of Combining Angiogenesis Inhibitors with Chemotherapy for Advanced Breast Cancer
Overview
Expand on the implications of improved PFS and response rates versus the lack of OS benefit.
Background
Breast cancer is the most common malignancy among women, with a significant proportion progressing to advanced stages that are largely incurable. Current chemotherapy regimens have reached a plateau in efficacy, highlighting the need for innovative treatment strategies. Anti-angiogenic therapies targeting VEGF/VEGFR2 have been explored, but their clinical benefits in advanced breast cancer remain controversial.
Data Highlights
Outcome
Result
Progression-Free Survival (PFS)
HR 0.75
Overall Survival (OS)
HR 0.95
Objective Response Rate (ORR)
Improved (P<0.001)
Clinical Benefit Rate (CBR)
Improved (P<0.001)
Disease Control Rate (DCR)
Improved (P<0.001)
Key Findings
Adding angiogenesis inhibitors to chemotherapy significantly improves PFS (HR 0.75).
No significant OS benefit was observed (HR 0.95, P = 0.171).
mAbs (e.g., bevacizumab) showed greater PFS benefit in TNBC compared to TKIs (HR 0.59 vs. 0.75).
TKIs trended better in HR+ disease (HR 0.67).
Increased safety risks include hypertension (OR 4.59) and thrombocytopenia (OR 4.54).
Benefit was more pronounced in patients without bone metastasis.
Clinical Implications
Clinicians should consider the improved PFS and response rates when combining angiogenesis inhibitors with chemotherapy for advanced breast cancer, particularly in TNBC and HR+ subtypes. However, the lack of OS benefit and increased toxicity necessitate careful patient selection and management of adverse effects.
Conclusion
The addition of angiogenesis inhibitors to chemotherapy offers significant improvements in PFS and response rates in advanced breast cancer, but does not enhance overall survival. The increased risk of toxicities requires proactive management strategies.
The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society of Clinical Oncology (ASCO) annual meeting May 29 to June 2 at McCormick Place in Chicago
